- Home
- RQI vs MNKD Comparison
RQI vs MNKD Comparison
Compare RQI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | MNKD |
|---|---|---|
| Founded | 2002 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | RQI | MNKD |
|---|---|---|
| Price | $12.83 | $2.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.64 |
| AVG Volume (30 Days) | 484.2K | ★ 6.3M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $33.40 |
| Revenue Next Year | N/A | $16.48 |
| P/E Ratio | ★ N/A | $130.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $10.39 | $2.59 |
| 52 Week High | $13.39 | $6.51 |
Technical Indicators
Market Signals| Indicator | RQI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 16.63 |
| Support Level | $12.14 | N/A |
| Resistance Level | $13.38 | $6.08 |
| Average True Range (ATR) | 0.20 | 0.38 |
| MACD | -0.07 | -0.21 |
| Stochastic Oscillator | 36.96 | 4.19 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.